Protein kinase C inhibitor prevents renal apoptotic and fibrotic changes in response to partial ureteric obstruction

Yung-Shun Juan1, Shu-Mien Chuang, Cheng-Yu Long

  • 1Graduate Institute of Medicine,Kaohsiung Medical University, Kaohsiung, Taiwan.

BJU International
|December 8, 2011
PubMed
Abstract

Insights

Protein kinase C inhibitor (PKCI) treatment protects renal function in obstructive nephropathy by reducing cell apoptosis and fibrosis. This study highlights PKCI

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Protein kinase C (PKC) pathway activation is implicated in diabetic nephropathy.
  • The role of PKC in obstructive nephropathy is not well understood.
  • Partial unilateral ureteric obstruction (PUUO) in rats causes renal damage.

Purpose of the Study:

  • To investigate PKC pathway expression following PUUO.
  • To evaluate the therapeutic potential of a PKC inhibitor (PKCI) in obstructive nephropathy.

Main Methods:

  • Rats underwent sham surgery or PUUO, with one PUUO group treated with PKCI (chelerythrine).
  • Renal morphology, hydronephrosis, cell apoptosis, mitosis, and interstitial fibrosis were assessed.
  • Western immunoblots analyzed fibronectin, TGF-β, and PKC isoform levels.

Main Results:

  • PUUO led to hydronephrosis, increased fibrosis, collagen, and fibronectin.
  • PUUO activated PKCα and PKCβ expression and translocation.
  • PKCI treatment reduced PKC expression/translocation, hydronephrosis, apoptosis, mitosis, and fibrosis.

Conclusions:

  • Obstructive nephropathy involves PKCα and PKCβ activation.
  • PKCI (chelerythrine) demonstrates therapeutic potential for protecting renal function post-PUUO.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...